2022

Innodia

IMPACT trial by IMCYSE completed recruitment

MELD-ATG trials opened for a younger cohort of people with newly diagnosed type 1 diabetes, ages 5 to 25.

2022

Innodia

IMPACT trial by IMCYSE completed recruitment

MELD-ATG trials opened for a younger cohort of people with newly diagnosed type 1 diabetes, ages 5 to 25.

2022

Innodia

IMPACT trial by IMCYSE completed recruitment

MELD-ATG trials opened for a younger cohort of people with newly diagnosed type 1 diabetes, ages 5 to 25.

Our founders

Eu facilisis sed odio morbi quis commodo. Urna nunc id cursus metusenectus et netus et malesuada fames ac. Magna sit amet purus gravida quis blandit turpis cursus inuis imperdiet massa tincidunt nunc.

INNODIA launch supported by:

Magna ac placerat vestibulum lectus

Lorem ipsum dolor sit, adipiscing consectetur elitunc maxi
musnulla ut commodo sagittis.

 

Innodia